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The new pathway nitrate–nitrite–nitric oxide (NO) has emerged as a physiological alternative to the
classical enzymatic pathway for NO formation from L-arginine. Nitrate is converted to nitrite by
commensal bacteria in the oral cavity and the nitrite formed is then swallowed and reduced to NO
under the acidic conditions of the stomach. In this study, we tested the hypothesis that increases in
gastric pH caused by omeprazole could decrease the hypotensive effect of oral sodium nitrite.
We assessed the effects of omeprazole treatment on the acute hypotensive effects produced by sodium
nitrite in normotensive and L-NAME-hypertensive free-moving rats. In addition, we assessed the changes
in gastric pH and plasma levels of nitrite, NOx (nitrateþnitrite), and S-nitrosothiols caused by treatments.
We found that the increases in gastric pH induced by omeprazole signiﬁcantly reduced the hypotensive
effects of sodium nitrite in both normotensive and L-NAME-hypertensive rats. This effect of omeprazole
was associated with no signiﬁcant differences in plasma nitrite, NOx, or S-nitrosothiol levels. Our results
suggest that part of the hypotensive effects of oral sodium nitrite may be due to its conversion to NO in
the acidiﬁed environment of the stomach. The increase in gastric pH induced by treatment with
omeprazole blunts part of the beneﬁcial cardiovascular effects of dietary nitrate and nitrite.
& 2012 Elsevier Inc.Open access under the Elsevier OA license.Introduction
The classical biological pathway for nitric oxide (NO) produc-
tion includes nitric oxide synthases (NOSs), which produce NO
from L-arginine, oxygen, and cofactors [1]. Part of the formed
NO rapidly reacts with oxygen to form NO2, which in solution
forms the anions nitrite (NO2
) and nitrate (NO3
) [2]. In vivo, NO2

reacts with oxyhemoglobin within erythrocytes to form NO3
 [3].
Interestingly, a balance between these NO-related species explains
the endogenous formation of NO2
/NO3
 and these markers of NO
formation have been used in clinical [4] and experimental studies
to reﬂect endogenous NO [5–7]. However, more recent research
has shown that NO2
 is more than a simple marker of NO formation
and can be recycled back to NO as a physiological alternative to NO
formation independent of NOS-related pathways [8–10].
Several different pathways have been suggested to form NO from
NO2
. These include enzymatic and nonenzymatic pathways includ-
ing interactions with deoxyhemoglobin [11], myoglobin [12,13],
xanthine oxidase [14,15], aldehyde oxidase [16], endothelial NOS
[17], mitochondrial cytochromes [18], and particular conditions such
as low-pH, acidic conditions of the stomach [19,20]. In this respect,1
@yahoo.com
sevier OA license.the ﬁrst study showing nonenzymatic NO production was reported
by Lundberg et al. in 1994 [21]. In a very elegant study, they showed
that intragastric NO production in humans was increased after
ingestion of lettuce, which is an important source of nitrate/nitrite,
and that NO generation was due to the low pH of the stomach [21].
In the same year, Benjamin et al. [19] also proposed that NO
formation in the stomach was an important defense mechanism
against swallowed pathogenic microorganisms [19]. Although many
enzymatic and nonenzymatic pathways have been proposed to
explain NO production from NO2, the relevance of each pathway to
the hypotensive effects of sodium nitrite is still poorly understood
[22]. In this study, we evaluate the relevance of low gastric pH to the
hypotensive effects associated with sodium nitrite. We aimed at
evaluating whether pretreating animals with omeprazole, a proton
pump inhibitor that increases gastric pH, could modify the hypoten-
sive effects associated with sodium nitrite. We hypothesized that
omeprazole could attenuate the antihypertensive effects exerted by
sodium nitrite given orally, but not intravenously.Materials and methods
Animals and treatments
This study was approved by the Institutional Animal Care and
Use Committee of the Faculty of Medicine of Ribeirao Preto,
L.C. Pinheiro et al. / Free Radical Biology and Medicine 53 (2012) 701–709702University of Sao Paulo, and the animals were handled according
to the guiding principles published by the National Institutes of
Health. Male Wistar rats (180–200 g) obtained from the colony at
the University of S~ao Paulo (Ribeirao Preto Campus, Brazil)
were maintained on a 12-h light/dark cycle at room temperature
(22–25 1C) with free access to standard rat chow and water.
Assessment of mean arterial pressure (MAP) in unanesthetized
free-moving rats
One day before the experiments, the animals were anesthe-
tized with tribromoethanol (250 mg/kg, ip) and the femoral artery
was cannulated (2-cm segment of a PE-10 tube connected to
14 cm of PE-50 tubing; Clay Adams, Parsippany, NJ, USA).
The catheter was then tunneled subcutaneously and exteriorized
through the back of the neck. In some experiments, the femoral
vein also was cannulated following the same procedures for
drug infusions. After surgery, the nonsteroidal anti-inﬂammatory
ﬂunixine meglumine (2.5 mg/kg, sc, Banamine; Schering Plough,
Brazil) was administered for postoperation analgesia. After 12 h of
fasting, the arterial cannula was connected to a pressure trans-
ducer and the MAP in freely moving rats was recorded using a
data acquisition system (MP150CE; Biopac Systems, CA, USA)
connected to a computer (Acknowledge 3.2 for Windows). When
collecting data, we allowed at least 15 min of stabilization before
or after each oral gavage.
Experimental protocols
This study included seven experimental protocols. In protocol
1, we examined whether pretreatment with omeprazole modiﬁes
the acute effects of oral sodium nitrite on the MAP of normoten-
sive rats. Therefore, after 12 h of fasting, the rats received a single
dose of vehicle (1 ml/kg 2% Tween 80) or omeprazole (a proton
pump inhibitor; 30 mg/kg) by gavage. Two hours later, the
rats received a single gavage of saline or sodium nitrite (15 or
45 mg/kg) and the changes in MAP were evaluated. The nitrite
doses used in this study were chosen on the basis of a previous
study showing that similar doses lowered the systolic blood
pressure by approximately 40 mm Hg in two two-kidney one-
clip hypertensive rats [22]. In addition, the dose of omeprazole
used in this study increased gastric pH to 5–6 [23].
In protocol 2, we examined whether pretreatment with ome-
prazole modiﬁes the acute effects of oral sodium nitrite on the
MAP of rats with No-nitro-L-arginine methyl ester hydrochloride
(L-NAME)-induced hypertension. Therefore, 1 h after vehicle or
omeprazole treatment (as described for protocol 1), the rats
received a single gavage of L-NAME (100 mg/kg) to increase the
MAP. This dose of L-NAME was chosen on the basis of pilot
studies showing that it increases MAP by approximately 40 mm
Hg. One hour after L-NAME treatment, the rats were treated with
saline or sodium nitrite (1, 5, 15, or 45 mg/kg, by gavage) and the
changes in MAP were evaluated.
In protocol 3, we examined whether the results obtained with
protocol 2 would be similar when hypertension was induced
by activating another mechanism. We examined whether pretreat-
ment with omeprazole modiﬁes the acute effects of oral sodium
nitrite on the MAP of rats with angiotensin II-induced hyperten-
sion. Two hours after vehicle or omeprazole treatment (as des-
cribed for protocol 1), we infused angiotensin II (200 ng/kg/min for
30 min) [24] to increase the MAP by approximately 40 mm Hg
(on the basis of pilot studies). After stabilization of hypertension,
the rats were treated with saline or sodium nitrite (5 mg/kg by
gavage) and the changes in MAP were evaluated.
In protocol 4, we examined whether the effects of omeprazole
on sodium nitrite-induced MAP reduction would be attenuatedwhen sodium nitrite was administered intravenously instead of
being administered orally (as in protocol 2). Therefore, we
compared the hypotensive effects of sodium nitrite (1, 5, 15 mg/
kg) administered intravenously to rats pretreated with omepra-
zole (or vehicle) and L-NAME exactly as described above for
protocol 2. In the three protocols, the changes in MAP after
vehicle or sodium nitrite treatment were assessed for 30 min.
In protocol 5, we aimed at examining whether the pH eleva-
tion associated with omeprazole underlies the effects of omepra-
zole on the hypotensive effects of orally administrated nitrite.
We examined the effects of sodium nitrite (15 mg/kg) adminis-
tered by oral gavage in buffered solutions (KH2PO4 0.2 M) at
pH 4 and at pH 6 compared to the respective vehicle. These
experiments were exactly as described for protocol 2.
In protocol 6, we examined whether omeprazole affects the
arterial blood pressure in rats treated with this drug for 14 day.
Twelve sham-operated rats received omeprazole (10 mg/kg; ip) or
vehicle and tail systolic blood pressure was assessed weekly by
tail-cuff plethysmography in conscious rats.
In protocol 7, we examined whether the effects of sodium
nitrite would be blocked by the NO scavenger 2-(4-carboxyphe-
nyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (C-PTIO). To
test this possibility, we infused saline (50 ml/min) or C-PTIO
(0.2 mg/kg/min) in L-NAME (100 mg/kg)-treated rats that
received sodium nitrite 15 mg/kg (or vehicle) by oral gavage,
and the changes in MAP were evaluated exactly as described for
protocol 2.
At the end of the experiments, arterial blood samples were
collected into tubes containing heparin and immediately centri-
fuged at 1000g for 3 min. Plasma aliquots were mixed with a
solution containing N-ethylmaleimide (10 mmol/L) and diethylene-
triaminepentaacetic acid (2 mmol/L) [25] to preserve S-nitro-
sothiols. The samples were stored at 70 1C until analyzed for
plasma nitrite, S-nitrosothiols, and NOx (nitrateþnitrite) levels. In
addition, the gastric washing pH was measured as described below.
Measurement of plasma nitrite and S-nitrosothiol concentrations
Plasma aliquots were analyzed in duplicate for their nitrite and
S-nitrosothiol content using an ozone-based reductive chemilu-
minescence assay as previously described [25,26]. Brieﬂy, to
measure nitrite concentrations in plasma, 50 ml of plasma sam-
ples was injected into a solution of acidiﬁed tri-iodide, purging
with nitrogen in line with a gas-phase chemiluminescence NO
analyzer (Sievers Model 280 NO analyzer; Boulder, CO, USA).
To measure S-nitrosothiol concentrations, the plasma samples
(400 ml) were treated with acid sulfanilamide (5% sulfanilamide in
1 M HCl) for 5 min before injection [25] into the solution of acidiﬁed
tri-iodide purged with nitrogen in line with the NO analyzer.
To discriminate S-nitrosothiols and other NO-related species,
plasma samples were treated with and without HgCl2 (5 mM) for
2 min, followed by a 3-min treatment with acidiﬁed sulfanilamide
before injection of the samples into acidiﬁed tri-iodide solution
[27]. However, the signal was below the detection limits when
the samples were treated with HgCl2, and therefore we were not
able to quantify other mercury-stable NO-related species.
Approximately 8 ml of tri-iodide solution (2 g of potassium
iodide and 1.3 g of iodine dissolved in 40 ml of water with 140 ml
of acetic acid) was placed in the purge vessel into which plasma
samples were injected. The data were analyzed using the software
Origin Lab 6.1.
Measurement of plasma NOx (nitrateþnitrite) concentration
The plasma NOx concentrations were determined in duplicate
by using the Griess reaction as described previously [28]. Brieﬂy,
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reductase buffer (0.1 M potassium phosphate, pH 7.5, containing
1 mM b-nicotinamide adenine dinucleotide phosphate and 2 U
f nitrate reductase/ml) in individual wells of a 96-well plate.
Samples were allowed to incubate overnight at 37 1C in the dark.
Eighty microliters of freshly prepared Griess reagent (1% sulfani-
lamide, 0.1% naphthylethylenediamine dihydrochloride in 5%
phosphoric acid) was added to each well and the plate was
incubated for an additional 15 min at room temperature. A
standard nitrate curve was obtained by incubating sodium nitrate
(0.2–200 mM) with the same reductase buffer.
Measurement of gastric washing pH
The abdominal cavity was opened and the pyloric portion of
the stomach was ligated. The lower portion of the esophagus was
opened and a catheter was introduced with its tip placed into the
stomach. A saline solution (1 ml, pH 4) was injected into the
stomach via this catheter and the gastric washing (0.5 ml) was
drawn, as previously described [23,29]. The gastric washing
samples were centrifuged at 6000g for 1 min to clean food debris
excess and the pH of the supernatant was assessed using a pH
microelectrode coupled to a bench pH meter (Jenway, Model
3510; Stone, Staffordshire, UK). To exclude the possibility of
alteration of gastric pH due to blood collection, some experiments
were performed without blood collection and the gastric washing
pH was assessed following the same procedures. We found no
signiﬁcant differences in gastric washing pH between these
approaches (data not shown).
Vascular reactivity
Wistar rats were killed by decapitation and their thoracic
aortas were isolated and cleaned of connective tissue and fat.
Aortic rings, 4 mm in length, were cut and mounted for isometric
tension recording as previously described [30]. The rings were
placed in bath chambers (5 ml) for isolated organs containing
modiﬁed Krebs salt solution with the following composition
(mM): NaCl 130, CaCl2 1.6, MgSO4 1.2, KH2PO4 1.2, KCl 4.7,
NaHCO3 14.9, glucose 5.5. The solution was kept at 37 1C,
pH 7.4, and bubbled with 95% O2 and 5% CO2. The system
was connected to an isometric force displacement transducer
(Harvard Apparatus, Holliston, MA, USA) and the responses were
recorded on a computer system using the LabChart version 4.0,
PowerLab ADInstruments (2000) program. The aortic rings were
subjected to a basal tension of 1.5 g during the 60-min equilibra-
tion period and were considered to have an intact functionalFig. 1. Mean arterial pressure in unanesthetized free-moving rats that received a singl
omeprazole (30 mg/kg) by gavage. (A) The MAP after each treatment and (B) the chan
group). N.S, not signiﬁcant; *Po0.05 (paired t test); #Po0.05 (two-way ANOVA).endothelium when acetylcholine (105 M) produced a relaxation
of more than 80%. Relaxation was calculated as a percentage of
the contraction induced by phenylephrine (107 M). We studied
the responses to cumulative concentrations (from 3108
to 103 M) of sodium nitrite in the presence or absence of
omeprazole (105 M) or vehicle (dimethyl sulfoxide (DMSO)
0.02%). Control experiments used modiﬁed Krebs salt solution.
The concentration–response curves were ﬁtted using a nonlinear
interactive ﬁtting program (GraphPad Prism 5.0; GraphPad
Software, Inc.).
Drugs and solutions
All drugs and reagents were purchased from Sigma Chemical
Co. (St Louis, MO, USA) and all solutions were prepared immedi-
ately before use.
Statistical analysis
The results are expressed as means7SEM. The comparisons
between groups were assessed by two-way analysis of variance. The
effects of nitrite infusions on MAP in each group were assessed by
paired t test. A probability value o0.05 was considered signiﬁcant.Results
Omeprazole reduces the acute hypotensive effect of sodium nitrite
administered orally
In the normotensive rats, sodium nitrite at 15 mg/kg by gavage
induced no signiﬁcant change in MAP in rats pretreated either
with vehicle or with omeprazole (P40.05; Figs. 1A and B).
Conversely, sodium nitrite at dose of 45 mg/kg by gavage sig-
niﬁcantly decreased the MAP by approximately 8 mm Hg and
pretreatment with omeprazole almost completely blunted this
effect (Po0.05; Figs. 1A and 1B).
After obtaining these interesting results, we decided to inves-
tigate whether pretreatment with omeprazole would result in
similar effects in hypertensive rats. Therefore we used L-NAME to
induce hypertension in rats and repeated the same experiments
using hypertensive rats. Interestingly, sodium nitrite used at 1, 5,
15, or 45 mg/kg by gavage exerted signiﬁcant, dose-dependent
antihypertensive effects (Po0.05; Figs. 2A and B). The pretreat-
ment with omeprazole signiﬁcantly attenuated these antihyper-
tensive effects at all doses of nitrite (Po0.05, Figs. 2A and B).
Importantly, pretreatment with omeprazole itself induced noe gavage of saline or sodium nitrite (15 or 45 mg/kg) 2 h after receiving vehicle or
ge elicited by each dose of nitrite. Data are shown as means7SEM (n¼8–12 per
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Fig. 2. Mean arterial pressure in unanesthetized free-moving rats that received a single gavage of saline or sodium nitrite (1, 5, 15, or 45 mg/kg) 2 h after receiving vehicle
or omeprazole (30 mg/kg) by gavage followed by L-NAME (100 mg/kg). (A) The MAP after each treatment and (B) the change elicited by each dose of nitrite. Data are
shown as means7SEM (n¼6–12 per group). N.S, not signiﬁcant; nPo0.05 (paired t test); #Po0.05 (two-way ANOVA).
Fig. 3. Mean arterial pressure in unanesthetized free-moving rats that received a single gavage of saline or sodium nitrite (5 mg/kg) 2 h after receiving vehicle or
omeprazole (30 mg/kg) by gavage followed by infusion of angiotensin II (200 ng/kg/min for 30 min). (A) The MAP after each treatment and (B) the change elicited by each
dose of nitrite. Data are shown as means7SEM (n¼4 per group). N.S, not signiﬁcant; nPo0.05 (paired t test); #Po0.05 (t test).
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Fig. 1A) or in L-NAME-treated hypertensive rats (P40.05; Fig. 2A).
To further conﬁrm that omeprazole attenuates the antihyper-
tensive effects exerted by nitrite, we studied the effects of sodium
nitrite at 5 mg/kg in angiotensin II-induced hypertension, in
animals pretreated with either omeprazole or vehicle. In line
with our results for L-NAME hypertension, sodium nitrite exerted
signiﬁcant antihypertensive effects in angiotensin II-induced
hypertension, which paralleled those found in L-NAME-treated
animals, and pretreatment with omeprazole signiﬁcantly attenu-
ated these effects (Po0.05; Figs. 3A and B).
Omeprazole does not modify the acute hypotensive effect
of intravenous sodium nitrite
Given that omeprazole attenuated the hypotensive effect of
sodium nitrite administered orally, we examined whether this
attenuation would also occur when sodium nitrite was administered
intravenously instead of orally. Therefore, we repeated the same
initial experiments with an important modiﬁcation: sodium nitritewas injected intravenously. Curiously, the intravenous injection of
sodium nitrite at 1, 5, or 15 mg/kg induced very similar hypotensive
effects in L-NAME-hypertensive rats pretreated with vehicle and in
rats pretreated with omeprazole (P40.05; Fig. 4).Effects of omeprazole on plasma nitrite, NOx, and S-nitrosothiol levels
Because differences in the responses to sodium nitrite between
rats pretreated with vehicle versus omeprazole could be due to
differences in the circulating levels of nitrites, we assessed the
plasma levels of nitrite and NOx in this study. As expected, we
found dose-dependent increases in plasma nitrite (Po0.05; Figs. 5A
and B) and NOx (Po0.05; Figs. 6A and B) in normotensive and in
L-NAME-hypertensive rats treated with sodium nitrite by gavage.
Treatment with omeprazole was associated with no signiﬁcant
differences in the increases in either nitrite or NOx concentration
in either normotensive or hypertensive rats (all Po0.05; Figs. 5
and 6). However, lower increases in both plasma nitrite and NOx
concentrations were found in L-NAME-hypertensive rats compared
Fig. 4. Mean arterial pressure in unanesthetized free-moving rats that received a single intravenous injection of saline or sodium nitrite (1, 5, or 15 mg/kg) 2h after
receiving vehicle or omeprazole (30 mg/kg) by gavage followed by L-NAME (100 mg/kg). (A) The MAP after each treatment and (B) the change elicited by each dose of
nitrite. Data are shown as means7SEM (n¼4 per group). N.S, not signiﬁcant; nPo0.05 (paired t test).
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Fig. 5. Plasma nitrite concentrations (mmol/L). (A) Plasma nitrite levels in normotensive rats that received a single gavage of saline (control) or sodium nitrite (15 or 45 mg/
kg) 2 h after receiving vehicle or omeprazole (30 mg/kg) by gavage. (B) Plasma nitrite levels in rats that received a single gavage of saline (control) or sodium nitrite
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means7SEM (n¼4–8 per group). nPo0.05 versus all other groups (two-way ANOVA).
Fig. 6. Plasma NOx (nitrateþnitrite; mmol/L) concentrations. (A) Plasma NOx concentrations in rats that received a single gavage of saline (control) or sodium nitrite
(15 or 45 mg/kg) 2 h after receiving vehicle or omeprazole (30 mg/kg) by gavage. (B) Plasma NOx concentrations in rats that received a single gavage of saline (control) or
sodium nitrite (1, 5, 15, or 45 mg/kg) 2 h after receiving vehicle or omeprazole (30 mg/kg) by gavage followed by L-NAME (100 mg/kg) or vehicle. Data are shown as
means7SEM (n¼6–8 per group). nPo0.05 versus all other groups (two-way ANOVA).
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(Po0.05; Figs. 5 and 6).
The plasma nitrite levels increased signiﬁcantly in L-NAME-
treated rats and in saline-treated controls that received sodiumnitrite intravenously at 1, 5, or 15 mg/kg (all Po0.05; Fig. 5C).
However, pretreatment with omeprazole had no effects on
the increases in plasma nitrite concentrations (all P40.05;
Fig. 5C).
Fig. 7. Plasma S-nitrosothiol (RSNO; nmol/L) concentrations in rats that received a
single gavage of saline or sodium nitrite (1, 5, or 15 mg/kg) 2 h after receiving
vehicle or omeprazole (30 mg/kg) by gavage followed by L-NAME (100 mg/kg) or
vehicle. Data are shown as means7SEM (n¼4–6 per group). *Po0.05 for both
L-NAMEþvehicle and L-NAMEþomeprazole groups versus their respective saline
controls (two-way ANOVA).
Fig. 8. Gastric washing pH in all experimental groups. After the hemodynamic
data was recorded, the gastric washing pH was assessed using a pH microelec-
trode. Data are shown as means7SEM (n¼4–8 per group). nPo0.05 (two-way
ANOVA).
Fig. 9. Vasorelaxation induced by sodium nitrite in aortic rings from rats. Aortic
rings were precontracted with phenylephrine (107 M) and the vasorelaxation
induced by various concentrations of sodium nitrite was assessed in the presence
or absence of omeprazole (105 M) and vehicle (DMSO 0.02%). Control experi-
ments used modiﬁed Krebs salt solution. Data are shown as means7SEM (n¼4–8
per group).
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We found increased plasma S-nitrosothiol concentrations in rats
treated with 5 or 15 mg/kg by gavage (both Po0.05; Fig. 7).
However, we found no effects of omeprazole on S-nitrosothiol
concentrations (P40.05; Fig. 7).
Effects of treatments on gastric pH
To evaluate the effects of various treatments on gastric pH and
to conﬁrm that omeprazole really increased gastric pH, we
measured gastric washing pH. Whereas a single oral dose of
omeprazole signiﬁcantly increased the gastric washing pH in both
normotensive and L-NAME-hypertensive rats (both Po0.05;
Fig. 8), treatment with L-NAME induced no signiﬁcant changes
in gastric washing pH, as suggested by very similar gastric
washing pH in normotensive and in L-NAME-hypertensive rats
(P40.05; Fig. 8).
Vasodilatation in rat aorta by nitrite
To examine the possibility that omeprazole could affect nitrite
vasorelaxant effects, we carried out experiments examiningwhether omeprazole affects nitrite-induced vasorelaxation in
isolated rat aorta. We found no signiﬁcant differences in nitrite
vasorelaxant effects in the presence or absence of omeprazole or
vehicle (P40.05; Fig. 9).
Gastric pH elevation associated with omeprazole underlies the effects
of omeprazole on the hypotensive effects of orally administrated
nitrite
To examine whether pH elevation associated with omeprazole
underlies the effects of omeprazole on the hypotensive effects of
orally administrated nitrite, we studied the effects of nitrite
administered in buffered solutions at pH 4 and pH 6 compared
to vehicle in rats pretreated with omeprazole and L-NAME.
We found that increasing gastric pH was associated with
decreased hypotensive effects caused by oral nitrite (Po0.05;
Fig. 10). We conﬁrmed that the buffer solutions controlled gastric
pH by measuring gastric pH, which resulted in pH 4.470.3 and
pH 6.070.1 when we used the buffered solutions at pH 4 and pH
6, respectively.
Omeprazole does not affect arterial Blood pressure
We examined whether omeprazole has any effects on arterial
pressure. We found no signiﬁcant effects of omeprazole on
systolic blood pressure in rats treated with this drug for 2 weeks.
Baseline and ﬁnal systolic blood pressures were 125711 and
126711 mm Hg in vehicle-treated rats, respectively, and 12679
and 12877 mm Hg in rats treated with omeprazole, respectively
(P40.05).
Effects of sodium nitrite in presence of C-PTIO infusion
To examine whether the effects of sodium nitrite are asso-
ciated with NO generation, we examined whether such effects
are attenuated by the NO scavenger C-PTIO. We found that
C-PTIO blocked the hypotensive effect of sodium nitrite by
480% (Po0.05; Fig. 11).Discussion
The main novel ﬁndings of this study were: (i) pretreatment
with omeprazole attenuated the hypotensive effects of oral
sodium nitrite, but not the hypotensive effects of sodium nitrite
administered intravenously; (ii) the hypotensive effects of oral
Fig. 10. Mean arterial pressure in unanesthetized free-moving rats that received a single gavage of saline or buffer solution of pH 4 or pH 6 with sodium nitrite (15 mg/kg)
2 h after receiving omeprazole (30 mg/kg) by gavage followed by L-NAME (100 mg/kg). (A) The MAP after each treatment and (B) the change in MAP induced by nitrite.
Data are shown as means7SEM (n¼6–8 per group). *Po0.05 (paired t test).
Fig. 11. Change in mean arterial pressure in unanesthetized free-moving rats that
received a single gavage of saline or sodium nitrite (15 mg/kg) with infusion of
saline (50 ml/min) or C-PTIO (0.2 mg/kg/min) after receiving L-NAME (100 mg/kg).
Data are shown as means7SEM (n¼6 per group). nPo0.05 (t test).
L.C. Pinheiro et al. / Free Radical Biology and Medicine 53 (2012) 701–709 707sodium nitrite are probably due, at least in part, to NO formation
in the stomach; and (iii) the attenuation of the hypotensive
effects exerted by sodium nitrite associated with omeprazole
pretreatment is probably not due to differences in the increases
in plasma nitrite, NOx, or S-nitrosothiol levels achieved after
sodium nitrite administration.
Several studies have reported vascular effects exerted by
sodium nitrite, which are ascribed to its bioconversion to NO
[8,9,31]. However, the mechanisms involved in this bioconversion
are not fully understood. Although there is increasing evidence
suggesting that several enzymes can convert nitrite to NO [32],
the excess of protons in the gastric juice has been shown to be an
important player in the conversion of nitrite to NO by none-
nzymatic reduction [20,21]. Our ﬁndings further support this idea
and show that the increases in gastric pH induced by omeprazole
impair the antihypertensive effects of sodium nitrite, thus sug-
gesting that a low stomach pH is very important for the beneﬁcial
vascular effects of sodium nitrite. Our ﬁndings may have impor-
tant clinical implications, especially for patients taking omepra-
zole or other proton pump inhibitors for any medical reason.
The ﬁrst report showing intragastric NO formation from nitrite
associated this ﬁnding with host defense against pathogens
swallowed with saliva and with a protective effect on the
integrity of the gastric mucosa [19,21]. Our ﬁndings expand these
previous observations and are consistent with the suggestion that
intragastric NO formation at the low pH of the stomach may
provide a different pathway to vasodilation and contribute to the
antihypertensive effects of sodium nitrite. Moreover, although wehave not tested this hypothesis in this study, it is possible that
omeprazole may also decrease the lowering effects on blood
pressure that have been shown in humans after a nitrate-rich
meal [33], or with the use of oral inorganic nitrates [34], which
may be reduced to nitrite and NO in rodent and human tissues
[35].
We and others have shown the nitrite exerts antihypertensive
effects in experimental models of hypertension [22,36–39]. In this
regard, it is reasonable to think that part of orally administered
nitrite is reduced to NO in the stomach and part diffuses into the
portal circulation, thus increasing the plasma nitrite levels [33].
Within the circulation, nitrite may be converted back to NO in the
vascular resistance vessels and cause vasodilatation, as previously
suggested [33]. Although we did not measure intragastric NO
formation in this study, we found that gastric pH elevation
associated with omeprazole underlies the effects of omeprazole
on the hypotensive effects of orally administrated nitrite, as
suggested by our results showing that increasing gastric pH
decreases the hypotensive effects caused by oral nitrite. Consis-
tent with these results, we found that the NO scavenger C-PTIO
blunted the hypotensive effects of oral nitrite almost completely.
In addition, we found very similar hypotensive effects when
sodium nitrite was administered intravenously to rats pretreated
with vehicle or with omeprazole, thus showing no effects of
omeprazole when nitrite is administered intravenously. More-
over, we found similar increases in plasma nitrite levels after
sodium nitrite was administered orally to rats previously treated
with omeprazole or vehicle, thus indicating that omeprazole had
no effects on the increases in circulating nitrite levels after
sodium nitrite administration. In other words, omeprazole had
no effects on the circulating nitrite concentrations available to
promote hypotensive effects. Together, these results clearly show
that omeprazole modiﬁes the hypotensive effect of sodium nitrite
administered orally, but not intravenously, and strongly suggest
that the pH of the stomach is relevant to the hypotensive effect
exerted by sodium nitrite and that omeprazole possibly blunts
intragastric NO formation.
It should be clear, however, that the mechanism explaining
nitrite-induced vasodilation (and antihypertensive effect) is not
determined only by intragastric NO formation. Indeed, intragas-
tric nitrite conversion to NO may provide an additional, different
pathway to vasodilation, possibly decreasing blood pressure as a
result of dilation of the splanchnic bed and reduction of preload.
This suggestion is based on previous ﬁndings showing that adding
nitrite to the stomach induces NO diffusion to the gastric
vasculature [40]. Moreover, the impaired hypotensive effects of
sodium nitrite in the presence of omeprazole could be due to
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nitrite present in the acidic environment of the stomach could
enhance the formation of nitrous acid, which could diffuse and
react with thiols and ferrous hemes, thus forming other relevant
NO-related species [40] potentially affecting the vasculature.
However, although we found increased S-nitrosothiol levels when
sodium nitrite was used at 5 or 15 mg/kg, omeprazole had no
effects on the increases in S-nitrosothiol levels, thus suggesting
that other mechanisms possibly involving NO-related species
other than S-nitrosothiols may be modiﬁed by omeprazole.
Interestingly, although omeprazole decreased the hypotensive
effects of oral sodium nitrite, this proton pump inhibitor did not
completely abolish the hypotensive effects, thus suggesting that
other mechanisms are involved in nitrite-induced hypotension.
Whereas the administration of sodium nitrite increased plasma
nitrite levels, most of it may have been rapidly converted to
nitrate, as suggested by the signiﬁcant increases in plasma NOx
levels (which reﬂect mainly nitrates content). Indeed, although
the low dose of sodium nitrite could result in increases in plasma
nitrite levels to 100 mmol/L or higher, the plasma nitrite levels
remained below 10 mmol/L. Similar results were found with the
higher sodium nitrite dose. These results suggested that nitrites
may be actively converted to nitrates, so that using much higher
doses of sodium nitrite may be ineffective. Conversely, some
studies reported that acute administration of nitrates results in
increased plasma nitrite levels [34,41]. We believe that these
issues deserve much more detailed study.
Another interesting observation is that we found lower
increases in plasma nitrite levels in L-NAME-hypertensive rats
than in normotensive rats after treatment with oral sodium
nitrite at 45 mg/kg, and this difference tended to be paralleled
by NOx levels. The reason for this difference is not clear. Although
it is possible that L-NAME may have reduced gastric blood ﬂow,
and therefore decreased gastric sodium nitrite absorption, other
mechanisms may be involved.
This study has some limitations. It is possible that differential
pharmacokinetics for nitrite absorption and metabolism exists
in rats treated with omeprazole, and a more complete time-
dependent assessment of plasma nitrite and S-nitrosothiols
could solve this issue. Using our methodologies, this would
require huge volumes of blood samples to be drawn from rats,
and this is not possible. In addition, we have not measured the
circulating concentrations of nitrosylhemoglobin (NO-Hb),
which results from the reaction between NO and hemoglobin.
Although NO-Hb does not exert potent biological effects, its
concentrations increased in blood after nitrite was injected in
the jejunum of rats [42]. Interestingly, it was shown that nitrite
instillation in the jejunum decreased arterial blood pressure
when NO-Hb achieved 10 mM concentration, and this was
suggested as a level required for initiating vasorelaxation, even
though the authors did not provide evidence that the hypoten-
sion was due to NO release from NO-Hb [42]. In addition, we
found no signiﬁcant increase in NO-Hb concentrations in rats
treated with nitrite at 15 mg/kg for 4 weeks in a previous study
[43]. Notwithstanding these criticisms, we believe that our
ﬁndings are of major importance and very consistent. We carried
out a number of different experiments to support the idea that
gastric pH has a major effect on the hypotension induced by oral
nitrite. This is really important because it suggests that patients
taking omeprazole or other drugs that modify gastric pH are
probably missing an important, protective effect of nitrite in the
diet. Many patients take this kind of drug and the reduction in
nitrite-induced hypotension by omeprazole may predispose
such patients, especially cardiovascular patients, to cardiovas-
cular events, although we do not have a precise mechanism to
explain how this happens.In conclusion, our ﬁndings are consistent with the idea that
part of the hypotensive effect of sodium nitrite given orally is due
to its conversion to NO in the acidiﬁed environment of the
stomach. The increases in gastric pH induced by omeprazole
clearly impair the hypotensive effect of sodium nitrite and this
experimental ﬁnding may have important clinical implications,
especially in patients taking proton pump inhibitors, because
these drugs may decrease the beneﬁcial effects of dietary nitrites
and nitrates.Acknowledgments
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